ABBV Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Adjusted Earnings Per Share (EPS): $1.86, exceeding guidance by $0.10.
Total Net Revenues: Nearly $15.8 billion, reflecting high single-digit sales growth and beating expectations by approximately $300 million.
Adjusted Gross Margin: 83.9% of sales.
Adjusted R&D Expense: 14.3% of sales, with a projected $9 billion for 2025.
Free Cash Flow: Approximately $13 billion generated in the first 9 months of the year.
Dividend Increase: Announced a 5.5% increase in quarterly cash dividend, starting February 2026.

2. Strategic Updates and Business Highlights

Immunology Growth: Combined sales growth of over 40% from Skyrizi and Rinvoq, with Skyrizi achieving $4.7 billion and Rinvoq nearly $2.2 billion in global sales.
Pipeline Advancements: Approximately 90 programs across all stages of development, with key upcoming milestones including new product approvals and expanded indications for existing therapies.
Acquisitions: Completed acquisitions of Gilgamesh (psychedelic therapy for MDD) and Capstan Therapeutics (in vivo CAR-T platform), enhancing pipeline capabilities.
Investment in Manufacturing: Commitment to invest at least $10 billion in U.S. facilities over the next decade, including new API manufacturing and biologics capacity expansions.

3. Forward Guidance and Outlook

2025 Guidance Update: Adjusted EPS guidance raised to between $10.61 and $10.65, with total net revenues expected to be approximately $16.9 billion.
2026 Outlook: Anticipated continued strong growth driven by Skyrizi, Rinvoq, and the neuroscience portfolio, despite headwinds from Humira erosion and Imbruvica IRA pricing.

4. Bad News, Challenges, or Points of Concern

Humira Erosion: Global sales of Humira down 55.7% to $993 million due to biosimilar competition, with expectations of further declines.
Aesthetics Market Pressure: Aesthetics segment sales down 4.2%, facing macroeconomic headwinds and low consumer sentiment affecting discretionary spending.
Competitive Pressures: Anticipated competition from new entrants in the IL-23 market, particularly with the introduction of TREMFYA.
IRA Pricing Impact: Although the impact on long-term guidance is minimal, deeper discounts from IRA negotiations could affect 2026 outlook.

5. Notable Q&A Insights

PBM Model Adaptability: Management expressed confidence in adapting to potential changes in the PBM model, emphasizing the importance of differentiated medicines.
Market Dynamics in Aesthetics: Leading indicators for a rebound include consumer confidence and sentiment towards HA fillers, with ongoing investments in marketing and training to stimulate growth.
Rinvoq Label Expansion: The enhanced IBD label is expected to provide a net positive impact, although specific quantification is not yet available.
Focus on Long-Term Growth: Management reiterated a commitment to long-term growth strategies, emphasizing the importance of pipeline depth and innovation across core therapeutic areas.

Overall, AbbVie reported strong financial performance in Q3 2025, with significant growth in immunology and neuroscience, while navigating challenges in aesthetics and the ongoing erosion of Humira sales. The company remains focused on strategic investments and pipeline advancements to drive future growth.

ABBV — AbbVie Inc.

Q3 2025 Earnings Call Summary